VERICEL CORPORATION - COMMON STOCK
57.78
19-二月-25 16:45:00
15 分钟延时
股票
+0.50
+0.87%
今日范围
56.72 - 58.16
ISIN
N/A
来源
NASDAQ
-
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
25 10月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
28 9月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
20 9月 2023 16:30:00 条件 Nasdaq GlobeNewswire
-
Vericel to Present at the Morgan Stanley Global Healthcare Conference
06 9月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
02 8月 2023 07:55:00 条件 Nasdaq GlobeNewswire
-
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
20 7月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
10 5月 2023 07:55:00 条件 Nasdaq GlobeNewswire
-
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
26 4月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
28 2月 2023 08:30:00 条件 Nasdaq GlobeNewswire
-
23 2月 2023 07:55:00 条件 Nasdaq GlobeNewswire
-
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
09 2月 2023 08:00:01 条件 Nasdaq GlobeNewswire
-
10 1月 2023 07:55:00 条件 Nasdaq GlobeNewswire
-
04 1月 2023 08:34:47 条件 Nasdaq GlobeNewswire
-
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
29 12月 2022 13:45:00 条件 Nasdaq GlobeNewswire
-
10 11月 2022 09:00:01 条件 Nasdaq GlobeNewswire
-
Vericel Reports Third Quarter 2022 Financial Results
09 11月 2022 07:55:00 条件 Nasdaq GlobeNewswire
-
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
26 10月 2022 08:30:00 条件 Nasdaq GlobeNewswire
-
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
22 9月 2022 08:30:00 条件 Nasdaq GlobeNewswire
-
06 9月 2022 08:30:00 条件 Nasdaq GlobeNewswire
-
Vericel Reports Second Quarter 2022 Financial Results
03 8月 2022 07:55:00 条件 Nasdaq GlobeNewswire